Last updated on May 2020

Spiolto Respimat (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT )

Brief description of study

Open-label comparative multicentric cohort study in COPD patients with LABA/ICS, switched to either tiotropium/olodaterol and observed for 12 weeks approximately.

Detailed Study Description

COPD patients on LABA/ICS maintenance therapy with dyspnea (mMRC 1) and other symptoms (CATTM 10), who are switched to either Spiolto Respimat in the new reusable inhaler or any triple therapy (LAMA + LABA + ICS) as an open or fixed combination according to approved SmPCs at baseline at the discretion of their attending physician.

Clinical Study Identifier: NCT03954132

Find a site near you

Start Over

Praxis Dr. Schmorell

Forchheim, Germany
  Connect »